383 related articles for article (PubMed ID: 27288955)
21. Treatment for patients with newly diagnosed multiple myeloma in 2015.
Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF
Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881
[TBL] [Abstract][Full Text] [Related]
22. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
23. [Induction therapy and the role of stem cell transplantation in the treatment of myeloma multiplex in patients aged below 65 years].
Stamatović D; Tukić L; Balint B
Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():103-9. PubMed ID: 22352191
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic stem cell transplantation for multiple myeloma.
Bensinger W
Hematol Oncol Clin North Am; 2014 Oct; 28(5):891-902. PubMed ID: 25212888
[TBL] [Abstract][Full Text] [Related]
25. Treatment of transplant-eligible patients with multiple myeloma in 2014.
Landau H; Giralt S
Hematol Oncol Clin North Am; 2014 Oct; 28(5):815-27. PubMed ID: 25212884
[TBL] [Abstract][Full Text] [Related]
26. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Voorhees PM; Usmani SZ
Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
[TBL] [Abstract][Full Text] [Related]
27. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
28. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Nishihori T; Alsina M
Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
[TBL] [Abstract][Full Text] [Related]
29. Second autologous transplant as salvage therapy in multiple myeloma.
Atanackovic D; Schilling G
Br J Haematol; 2013 Dec; 163(5):565-72. PubMed ID: 24111632
[TBL] [Abstract][Full Text] [Related]
30. The future of autologous stem cell transplantation in myeloma.
van Rhee F; Giralt S; Barlogie B
Blood; 2014 Jul; 124(3):328-33. PubMed ID: 24894774
[TBL] [Abstract][Full Text] [Related]
31. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well.
Martino M; Morabito F
Expert Opin Biol Ther; 2015 Feb; 15(2):149-54. PubMed ID: 25435056
[TBL] [Abstract][Full Text] [Related]
32. Controversies in multiple myeloma: to transplant or not?
Preeshagul IR; Van Besien K; Mark TM
Curr Hematol Malig Rep; 2014 Dec; 9(4):360-7. PubMed ID: 25145553
[TBL] [Abstract][Full Text] [Related]
33. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Cavo M; Rajkumar SV; Palumbo A; Moreau P; Orlowski R; Bladé J; Sezer O; Ludwig H; Dimopoulos MA; Attal M; Sonneveld P; Boccadoro M; Anderson KC; Richardson PG; Bensinger W; Johnsen HE; Kroeger N; Gahrton G; Bergsagel PL; Vesole DH; Einsele H; Jagannath S; Niesvizky R; Durie BG; San Miguel J; Lonial S;
Blood; 2011 Jun; 117(23):6063-73. PubMed ID: 21447828
[TBL] [Abstract][Full Text] [Related]
34. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
35. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
Moreau P; Giralt SA
Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
[TBL] [Abstract][Full Text] [Related]
36. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma: Role of autologous transplantation.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Kastritis E; Terpos E; Dimopoulos MA
Cancer Treat Rev; 2020 Jan; 82():101929. PubMed ID: 31770695
[TBL] [Abstract][Full Text] [Related]
39. The role of transplant in multiple myeloma.
Mei M; Somlo G
J Natl Compr Canc Netw; 2014 Aug; 12(8):1131-8. PubMed ID: 25099445
[TBL] [Abstract][Full Text] [Related]
40. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
